Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexverapamil
- Development stage
- Approved
- Lead developer
- Knoll
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Sublingual, Topical, Rectal
01
Overview
Dexverapamil is the R-enantiomer of verapamil, a phenylalkylamine calcium channel blocker. Unlike racemic verapamil or its S-enantiomer counterpart, dexverapamil exhibits significantly reduced calcium antagonistic activity and toxicity. Its primary mechanism of action is as a competitive inhibitor of the multidrug resistance efflux pump P-glycoprotein (MDR-1/ABCB1), which can increase the effectiveness of various antineoplastic drugs by preventing their expulsion from cancer cells. This property has led to its investigation as a chemosensitizer and modulator of multidrug resistance in oncology settings[1][4][5]. Developed primarily for experimental use in combination with cancer chemotherapy regimens to overcome drug resistance mechanisms[5].
- Brand names
- DexvérapamilDexverapamiloDexverapamilum
- Other names
- dexverapamil hydrochloride
02
Targets
ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on dexverapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexverapamil.